Karla Emanuelly Ribeiro De Lima, Maria Graziela de Fátima Alvarez Kenupp

Karla Emanuelly Ribeiro De Lima, Aluna de Medicina – Universidade Federal do Ceará – Ceará – BRA; ORCID: 0009-0005-0945-2315 (https://orcid.org/0009-0005-0945-2315); E-mail: karla.lima17@aluno.ce.gov.br

Maria Graziela de Fátima Alvarez Kenupp, Aluna de Medicina – Universidad Nacional Ecologica – SCZ – BOL; ORCID: 0009-0001-3768-9900 (https://orcid.org/0009-0001-3768-9900); E-mail: maria53679@uecologica.edu.bo

Corresponding Author: Uyeda, Mari. PhD in Oncology – A.C. Camargo Cancer Center, Pos Doctoral Student – A.C. Camargo Cancer Center, Medical Student – ​​Universidad Nacional Ecológica.

Email: mari53972@uecologica.edu.bo; ORCID: 0000-0002-9490-6000 (https://orcid.org/0000-0002-9490-6000.

Citation: Karla Emanuelly Ribeiro De Lima, Maria Graziela de Fátima Alvarez Kenupp (2025) Use of Immunosuppressants in the Treatment of Chronic Dermatologi- cal Diseases. J Skin Care Res Rep, 2(1);01-08.

Copy Rights: @2025,  Karla Emanuelly Ribeiro De Lima, This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: Chronic dermatological diseases represent significant challenges for patients and physicians due to their inflammatory and recurrent nature. Treatment of these conditions often requires the use of immunosuppressants, which act by modulating the immune response to reduce inflammation and control symptoms. However, their prolonged use may be associated with adverse effects, requiring strict monitoring to ensure the safety and efficacy of the treatment. Methodology: To understand the efficacy of immunosuppressants in the treatment of these diseases, a literature review was performed, analysing scientific articles, medical guidelines and clinical studies published in databases such as PubMed, SciELO and Embase. The mechanisms of action of the main immunosuppressants were evaluated, in addition to the clinical impacts and recommendations for the safe management of patients. Results: Studies indicate that immunosuppressants provide significant improvement in dermatological symptoms, reducing skin inflammation and preventing systemic complications. However, the results also point to adverse effects, such as opportunistic infections, liver toxicity and increased risk of neoplasia, especially in patients requiring prolonged immunosuppressive therapies. In addition, new therapeutic approaches, such as JAK and monoclonal antibodies, present greater specificity in modulating the immune response and a lower incidence of serious side effects. Discussion: The use of immunosuppressants in the treatment of chronic dermatological diseases is essential for controlling inflammation and improving the quality of life of patients. However, the literature reinforces the need for careful monitoring, with periodic exams to assess the liver, kidney and hematologic function of patients undergoing treatment. In addition, the evolution of medical research has led to the development of safer and more effective therapies, allowing a more personalised approach adapted to the individual characteristics of each patient. Conclusion: Treatment with immunosuppressants remains a fundamental strategy for the management of chronic dermatological diseases, ensuring greater control of symptoms and reducing the negative impacts of these conditions on the lives of patients. However, the challenges related to adverse effects require rigorous medical monitoring and the search for safer therapeutic alternatives. Continuous research in the area of ​​immunomodulation has been essential to improve treatment options, allowing advances in the personalisation of therapies and patient safety.

Keywords: Immunosuppressants, Psoriasis, Severe Atopic Dermatitis, Systemic Lupus Erythematosus, Pyoderma Gangrenosum.